Stimulation of insulin secretion by infusion of free fatty acids.
The acute elevation of plasma free fatty acid (FFA) levels by direct infusion of sodium oleate into the plasma of conscious dogs was accompanied by the rapid onset of a 2- to 12-fold increase in plasma immunoreactive insulin, and, subsequently, a marked fall in plasma glucose, even in dogs receiving intravenous glucose throughout the infusion. The magnitude of both the insulin and glucose responses correlated with the mean FFA level during infusion. A large increase in plasma insulin and fall in glucose also occurred when glycerol was infused with oleate in order to simulate endogenous lipolysis more closely. Insulin levels in pancreaticoduodenal vein blood rose markedly during oleate infusion, while plasma ketone levels rose only slightly. In contrast to the effects of oleate infusion, elevation of plasma FFA to correspondingly high levels by triolein ingestion and intravenous heparin produced only small increases in plasma insulin, which did not correlate well with the FFA level reached, and small increases in plasma glucose.The results indicate that under certain conditions elevated FFA levels may be a potent stimulus of insulin secretion. This response is modified under other conditions such as during chylomicron removal under the influence of heparin. This effect may play a role in the regulation of lipolysis and ketone formation, but determination of the exact mechanism of FFA stimulation of the pancreas and its physiological significance will require further investigation.
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004041:Dietary Fats; D004285:Dogs; D005230:Fatty Acids, Nonesterified / Q000008:administration & dosage* / Q000097:blood / Q000502:physiology*; D005260:Female; D005990:Glycerol / Q000008:administration & dosage; D006493:Heparin / Q000008:administration & dosage; D007275:Injections, Intravenous; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007659:Ketones / Q000097:blood; D050356:Lipid Metabolism; D008297:Male; D009829:Oleic Acids / Q000008:administration & dosage; D010179:Pancreas / Q000187:drug effects
D001786:Blood Glucose; D004041:Dietary Fats; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D007659:Ketones; D009829:Oleic Acids; D006493:Heparin; D005990:Glycerol
Diabetes. 1965 Dec;14(12):771-9
5850216
J Clin Invest. 1965 Dec;44(12):2010-20
5851958
J Clin Invest. 1966 Feb;45(2):228-36
5901508
Am J Physiol. 1967 Apr;212(4):747-55
6024435
Metabolism. 1967 May;16(5):482-4
6025027
Can J Physiol Pharmacol. 1967 Jan;45(1):29-38
6030400
Diabetes. 1967 Nov;16(11):765-76
6072699
Lancet. 1967 Dec 23;2(7530):1334-6
4170031
Nature. 1968 Mar 2;217(5131):853
4867975
Metabolism. 1968 Apr;17(4):301-4
5646200
Rev Fr Etud Clin Biol. 1968 Jan;13(1):62-7
5653558
J Lab Clin Med. 1968 Aug;72(2):290-7
5302341
J Lab Clin Med. 1968 Sep;72(3):438-48
5674075
N Engl J Med. 1969 Apr 10;280(15):820-8
4886501
J Clin Invest. 1969 Oct;48(10):1923-33
5822596
Lancet. 1963 Apr 13;1(7285):785-9
13990765
J Clin Invest. 1964 Mar;43:408-15
14135491
J Clin Invest. 1964 Apr;43:638-46
14149917
J Lab Clin Med. 1964 Feb;63:177-92
14125105
J Clin Invest. 1960 Mar;39:507-22
14419685